Phospho-specific antibodies’ typical purpose is to enable researchers to detect changes in proteins. They will exclusively bind to the amino acid sequence on a protein that has been phosphorylated (which is both a physical & chemical change) and do not bind to the same amino acid sequence on said protein if it lacks said phosphorylation. This aids in being able to clearly see and understand the data produced from this particular protein modification.
WB (Western Blot) (Western blot analysis of Phospho-RAF1-pS338 Antibody in human TPA activated Hela cell line lysates. Phospho-RAF1 (arrow) was detected using the purified PAb. (0: without TPA; 1: 60ug/ml TPA, 15min; 2: 60ug/ml TPA, 30min; 3: 60ug/ml TPA, 45min; 4: 125ug/ml TPA, 15min; 5: 125ug/ml TPA, 30min; 6: 125ug/ml TPA, 45min; 7: 250ug/ml TPA, 15min; 8: 250ug/ml TPA, 30min; 9: 250ug/ml, 45min))
DB (Dot Blot) (Dot blot analysis of anti-RAF1-pS338 Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
DB (Dot Blot) (Dot blot analysis of anti-Phospho-GFAP-S8 Antibody on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
DB (Dot Blot) (Dot blot analysis of Phospho-IKKB-S672 Antibody Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.6ug per ml.)
IHC (Immunohistochemistry) (Formalin-fixed and paraffin-embedded human canccer tissue reacted with the primary antbody, which was peroxidase-conjugated to the secondary antibody, which followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemisty; clinical relevance has not been evaluated. BC= Breast Carcinoma; HC= Hepatocarcinoma.)
DB (Dot Blot) (Dot blot analysis of Phospho-Cdk7-T170 Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
WB (Western Blot) (Western blot analysis of extracts from Hela and MCF-7 cells, untreated or lamda phosphatase-treated, using Phospho-CDK7(please inquire) Antibody (upper) or Beta-actin (lower).)
WB (Western Blot) (Western blot analysis of lysates from NIH/3T3 cell line, untreated or treated with ? phosphatase, using 459667101(Cat. #AAA283874)(upper) or Tubulin (lower).)
WB (Western Blot) (The CDK7-T170 Pab is used in Western blot to detect CDK7-T170 in Ramos tissue lysate.)
DB (Dot Blot) (Dot blot analysis of Phospho-ERBB2-S1107 Antibody Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.6ug per ml.)
WB (Western Blot) (Western blot analysis of extracts from A431 cells, untreated or treated with EGF, using phospho-ERBB2-S1107 (left) or ErBB2 antibody(right).)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of PRAK (phospho-Thr182) staining in human breast carcinoma formalin fixed paraffin embedded tissue section. The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of PRAK (phospho-Thr182) expression in K562 Na3VO4 treated whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of PKC iota/zeta (phospho-Thr412/410) staining in MCF7 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 C in a hidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of PKC iota/zeta (phospho-Thr412/410) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of PKC iota/zeta (phospho-Thr412/410) expression in MCF7 TNFa-treated, NIH3T3 LPS-treated, PC12 UV-treated whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of RAD51A (phospho-Tyr315) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of RAD51A (phospho-Tyr315) expression in HeLa UV-treated, HEK293T UV-treated whole cell lysates.)
ICC (Immunocytochemistry) (ICC staining Phospho-p95/NBS1 (S343) in PC-3M cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded mouse testis tissue using anti-Phospho-p95/NBS1 (S343) antibody. Counter stained with hematoxylin.)
ICC (Immunocytochemistry) (ICC staining Phospho-c-Myc (S62) in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
WB (Western Blot) (Western blot analysis of Phospho-c-Myc (S62) on different lysates using anti-Phospho-c-Myc (S62) antibody at 1/1, 000 dilution. Positive control: Lane 1: A549 Lane 2: HCT116 Lane 3: Hela Lane 4: HepG2)
ICC (Immunocytochemistry) (ICC staining phospho-PKA R2 (S99) in MCF-7 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
ICC (Immunocytochemistry) (ICC staining phospho-PKA R2 (S99) in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
IHC (Immunohistochemisry) (Immunohistochemical analysis of paraffin-embedded mouse heart tissue using anti- phospho-PKA R2 (S99) antibody. Counter stained with hematoxylin.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded mouse testis tissue using anti- phospho-PKA R2 (S99) antibody. Counter stained with hematoxylin.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human spleen tissue using anti- phospho-PKA R2 (S99) antibody. Counter stained with hematoxylin.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using anti- phospho -SMC1 (S957) antibody. Counter stained with hematoxylin.)
IHC (Immunohistochemisry) (Immunohistochemical analysis of paraffin-embedded human lung cancer tissue using anti- phospho -SMC1 (S957) antibody. Counter stained with hematoxylin.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti- phospho -SMC1 (S957) antibody. Counter stained with hematoxylin.)
WB (Western Blot) (Western blot analysis of SMC1 (phospho S957) on Hela cells lysates using anti- phospho -SMC1 (S957) antibody at 1/1, 000 dilution.)
ICC (Immunocytochemistry) (ICC staining phospho -Tau (S396) in PC12 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
ICC (Immunocytochemistry) (ICC staining phospho -Tau (S396) in N2A cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded mouse brain tissue using anti- phospho -Tau (S396) antibody. Counter stained with hematoxylin.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded rat brain tissue using anti- phospho -Tau (S396) antibody. Counter stained with hematoxylin.)
FCM/FACS (Flow Cytometry) (Flow cytometric analysis of Hela cells with Phospho-Smad2 (S250) antibody at 1/50 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). Alexa Fluor 488-conjugated goat anti rabbit IgG was used as the secondary antibody)
WB (Western Blot) (Western blot analysis of Phospho-Smad2 (S250) on Hela cells lysates using anti-Phospho-Smad2 (S250) antibody at 1/1, 000 dilution.)
ICC (Immunocytochemistry) (ICC staining Phospho-Hsp27 (S78) in NIH/3T3 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
ICC (Immunocytochemistry) (ICC staining Phospho-Hsp27 (S78) in MCF-7 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
ICC (Immunocytochemistry) (ICC staining Phospho-Hsp27 (S78) in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using anti-Phospho-Hsp27 (S78) antibody. Counter stained with hematoxylin.)
WB (Western Blot) (Western blot analysis of Phospho-Hsp27 (S78) on different lysates using anti-Phospho-Hsp27 (S78) antibody at 1/1, 000 dilution. Positive control: Lane 1: Human heart Lane 2: Human skeletal muscle)
ICC (Immunocytochemistry) (ICC staining Phospho-Rac1+Cdc42 (Ser71) in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
ICC (Immunocytochemistry) (ICC staining Phospho-Rac1+Cdc42 (Ser71) in A431 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human liver cancer tissue using anti-Phospho-Rac1+Cdc42 (Ser71) antibody. Counter stained with hematoxylin.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human lung cancer tissue using anti-Phospho-Rac1+Cdc42 (Ser71) antibody. Counter stained with hematoxylin.)
ICC (Immunocytochemistry) (ICC staining Phospho-PTEN (S380) in SW480 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
ICC (Immunocytochemistry) (ICC staining Phospho-PTEN (S380) in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
ICC (Immunocytochemistry) (ICC staining Phospho-PTEN (S380) in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.)
WB (Western Blot) (Western blot analysis of Phospho-PTEN (S380) on different lysates using anti-Phospho-PTEN (S380) antibody at 1/1, 000 dilution. Positive control: Lane 1: Human placenta Lane 2: Human lung)
IHC (Immunohistochemisry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
IF (Immunofluorescence) (Fluorescent confocal image of an SY5Y cell stained with AAA288354 Phospho-STAT5a antibody. SY5Y cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.2%, 30 min), then incubated with AAA288354 Phospho-STAT5a primary antibody (1:200, 2 h at room temperature). For secondary antibody, Alexa Fluor 488 conjugated donkey anti-rabbit antibody (green) was used (1:1000, 1h).Cytoplasmic actin was counterstained with Alexa Fluor 555 (red) conjugated Phalloidin (5.25 uM, 25 min). Nuclei were counterstained with Hoechst 33342 (blue) (10 ug/ml, 3 min)(not shown). Phospho-STAT5a immunoreactivity is localized exclusively to the nucleus.)
WB (Western Blot) (Western blot analysis of anti-Phospho-STAT5 Pab in HepG2 cell line lysate (35ug/lane). Phospho-STAT5(arrow) was detected using the purified Pab.)
IHC (Immunohistochemisry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
WB (Western Blot) (Western blot analysis of anti-Phospho-cJun-pS63 Pab in mouse kidney tissue lysate (35ug/lane). cJun-pS63 (arrow) was detected using the purified Pab.)
DB (Dot Blot) (Dot blot analysis of anti-Phospho-cJun-S63 Antibody on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
WB (Western Blot) (Western blot analysis of Phospho-MYC-T58 Antibody in human TPA activated Hela cell line lysates. Phospho-MYC (arrow) was detected using the purified PAb. (0: without TPA; 1: 60ug/ml TPA, 15min; 2: 60ug/ml TPA, 30min; 3: 60ug/ml TPA, 45min; 4: 125ug/ml TPA, 15min; 5: 125ug/ml TPA, 30min; 6: 125ug/ml TPA, 45min; 7: 250ug/ml TPA, 15min; 8: 250ug/ml TPA, 30min; 9: 250ug/ml, 45min))
DB (Dot Blot) (Dot blot analysis of Phospho-MYC-T58 Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
DB (Dot Blot) (Dot blot analysis of anti-Phospho-LIN28-S134 Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
IF (Immunofluorescence) (Fluorescent confocal image of SY5Y cells stained with phospho- LIN28- S134 antibody. SY5Y cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.2%, 30 min). Cells were then incubated with AAA289649 phospho- LIN28- S134 primary antibody (1:100, 2 h at room temperature). For secondary antibody, Alexa Fluor 488 conjugated donkey anti-rabbit antibody (green) was used (1:1000, 1h). Nuclei were counterstained with Hoechst 33342 (blue) (10 ug/ml, 5 min). Note the highly specific localization of the phospho- LIN28 immunosignal mainly to the nucleus, supported by Human Protein Atlas Data (http://www.proteinatlas.org/ENSG00000131914).)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using p16-INK4a (Phospho-Ser152) antibody. The picture on the right is treated with the synthesized peptide.)
WB (Western Blot) (Western blot analysis of extracts from HeLa cells, treated with EPO (20U/ml, 15mins), using p16-INK4a (Phospho-Ser152) antibody. The lane on the right is treated with the synthesized peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Connexin 43(Phospho-Ser367) Antibody (left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreated or treated with PMA using Connexin 43(phospho-Ser368) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
IHC (Immunohistochemisry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using NFkappaB-p65 (phospho-Ser311) antibody ().)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed HeLa cells using NFkappaB-p65 (phospho-Ser311) antibody (, Red).)
WB (Western Blot) (Western blot analysis of extracts from Hela cells untreated or treated with IFN-alpha using NFkappaB-p65((phospho-Ser311) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
DB (Dot Blot) (Dot blot analysis of Phospho-ERBB2-Y1139 Antibody Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.6ug per ml.)
WB (Western Blot) (Western blot analysis of extracts from A431 cells,untreated or treated with EGF,100ng/ml, using phospho-ERBB2-Y1139(left) or ERBB2 antibody(right))
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
WB (Western Blot) (Western blot analysis of anti-Phospho-STAT1 Pab in mouse brain tissue lysate (35ug/lane). Phospho-STAT1(arrow) was detected using the purified Pab.)
The antibody was purified from rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
DB (Dot Blot) (Dot blot analysis of anti-Phospho-MAPKAPK2-S272 Antibody on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
IHC (Immunohistochemisry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
WB (Western Blot) (The anti-Phospho-CDC25B-S187 Pab is used in Western blot to detect Phospho-CDC25B-S187 in SK-BR-3 tissue lysate)
IF (Immunofluorescence) (Confocal immunofluorescent analysis of Phospho-SMAD2-T220 Antibody with Hela cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green).Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red).)
DB (Dot Blot) (Dot blot analysis of anti-Phospho-SMAD2-T220 Phospho-specific Pab (Cat. #AAA285432) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
WB (Western Blot) (Western blot analysis of lysates from Hela cell line, untreated or treated with TGF-β, 100ng/ml, 30min, using Phospho-SMAD2(T220) Antibody(Cat. #AAA285432)(upper) or Beta-actin (lower).)
Human Phospho-Vascular Endothelial Cell Growth Factor Receptor 2 ELISA Kit
Reactivity
Human
Pricing
WB (Western Blot) (Western blot analysis of extracts from 293 cells, transfected with Tau and treated with calf intestinal phosphatase (CIP) using Tau(Phospho-Thr217) Rabbit mAb.)
WB (Western Blot) (Western blot analysis of lysates from LOVO cells treated with Serum 10% 15', using SRF (Phospho-Ser99) Antibody. The lane on the right is blocked with the phospho peptide.)
IHC (Immunohistochemistry) (Immunohistochemistry analysis of paraffin-embedded human lung carcinoma, using SRF (Phospho-Ser99) Antibody. The picture on the right is blocked with the phospho peptide.)
Purified from rabbit antiserum by affinity-chromatography using phospho peptide. The antibody against non-phospho peptide was removed by chromatography using corresponding non-phospho peptide.
WB (Western Blot) (Western blot analysis of lysates from HepG2 cells, using WASP (Phospho-Tyr290) Antibody. The lane on the right is blocked with the phospho peptide.)
IHC (Immunohistochemistry) (Immunohistochemistry analysis of paraffin-embedded human brain, using WASP (Phospho-Tyr290) Antibody. The picture on the right is blocked with the phospho peptide.)
Purified from rabbit antiserum by affinity-chromatography using phospho peptide. The antibody against non-phospho peptide was removed by chromatography using corresponding non-phospho peptide.
WB (Western Blot) (Western blot analysis of lysates from HepG2 cells treated with EGF 200ng/ml 30', using ACK1 (Phospho-Tyr284) Antibody. The lane on the right is blocked with the phospho peptide.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using ACK1 (Phospho-Tyr284) Antibody. The picture on the right is blocked with the phospho peptide.)
IF (Immunofluorescence) (Immunofluorescence analysis of A549 cells, using ACK1 (Phospho-Tyr284) Antibody. The picture on the right is blocked with the phospho peptide.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Purified from rabbit antiserum by affinity-chromatography using phospho peptide. The antibody against non-phospho peptide was removed by chromatography using corresponding non-phospho peptide.
WB (Western Blot) (Western blot analysis of lysates from HepG2 cells treated with EGF 200ng/ml 30' and A549 cells treated with PMA 125ng/ml 30', using p130 Cas (Phospho-Tyr249) Antibody. The lane on the right is blocked with the phospho peptide.)
IHC (Immunohistochemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using p130 Cas (Phospho-Tyr249) Antibody. The picture on the right is blocked with the phospho peptide.)
Purified from rabbit antiserum by affinity-chromatography using phospho peptide. The antibody against non-phospho peptide was removed by chromatography using corresponding non-phospho peptide.
WB (Western Blot) (Western blot analysis of lysates from HeLa cells treated with TNF 2500U/ML 30', using p63 (Phospho-Ser455) Antibody. The lane on the right is blocked with the phospho peptide.)
IHC (Immunohistochemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using p63 (Phospho-Ser455) Antibody. The picture on the right is blocked with the phospho peptide.)
Purified from rabbit antiserum by affinity-chromatography using phospho peptide. The antibody against non-phospho peptide was removed by chromatography using corresponding non-phospho peptide.
WB (Western Blot) (Western blot analysis of lysates from 293 cells treated with Insulin 0.01U/ml 30', using Tyrosine Hydroxylase (Phospho-Ser19) Antibody. The lane on the right is blocked with the phospho peptide.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain, using Tyrosine Hydroxylase (Phospho-Ser19) Antibody. The picture on the right is blocked with the phospho peptide.)
IF (Immunofluorescence) (Immunofluorescence analysis of HUVEC cells, using Tyrosine Hydroxylase (Phospho-Ser19) Antibody. The picture on the right is blocked with the phospho peptide.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Purified from rabbit antiserum by affinity-chromatography using phospho peptide. The antibody against non-phospho peptide was removed by chromatography using corresponding non-phospho peptide.
WB (Western Blot) (Western blot analysis of lysates from NIH/3T3 cells treated with Serum 10% 30', using eEF2 (Phospho-Thr56) Antibody. The lane on the right is blocked with the phospho peptide.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using eEF2 (Phospho-Thr56) Antibody. The picture on the right is blocked with the phospho peptide.)
IF (Immunofluorescence) (Immunofluorescence analysis of HUVEC cells, using eEF2 (Phospho-Thr56) Antibody. The picture on the right is blocked with the phospho peptide.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Purified from rabbit antiserum by affinity-chromatography using phospho peptide. The antibody against non-phospho peptide was removed by chromatography using corresponding non-phospho peptide.
Immunoprecipitation, Immunofluorescence, Immunocytochemistry, Immunohistochemistry, Western Blot
Purity
Affinity-chromatography
Pricing
What Are Phospho Antibodies?
Protein phosphorylation is a process where a phosphate group is added to certain amino acid residues of a protein – usually serine (S), threonine (T), or tyrosine (Y) - by enzymes called kinases. This process is integral in controlling cellular signaling, cellular growth, and other biological functions.
Our catalog includes a wide range of phospho-specific antibodies that can accurately detect this important marker. They perform strongly in widely-used laboratory applications such as Western blot, flow cytometry, immunohistochemistry, and immunofluorescence microscopy. We value your trust in us and are committed to providing top-quality products and services. All of our antibodies are guaranteed to work for the applications and species indicated on our website & associated product pages.
What Are The Key Applications of Phospho Antibodies?
1. Western Blotting
One of the first steps a researcher can take in utilizing these phospho-specific antibodies, is to check if the antibody works using a technique referred to as “Western blot”. For those unfamiliar, Western Blot aids in showing whether the protein that the antibody recognizes is appearing at the correct/expected size. These phospho-specific antibodies should also be able to detect changes in the target protein’s phosphorylation (on/off state) when cells are stimulated in certain ways.
2. Staining of Fixed Cells (Immunocytochemistry)
Another routine use of these phospho-specific antibodies, is to test if the antibody is able to demonstrate similar performance when used on fixed cells (intact cells that have been preserved) as it did in the Western blot tests. It is an important aspect in many cases to confirm that the antibody works in actual intact cell samples. Ideally, the method used for cellular fixation should be the same as what is used in pathology labs (like using 10% formalin). To check if the antibody works well in tissue sections (FFPE), researchers will often test it on fixed cells that are processed similar to tissue samples.
3. Specificity Tests Using Peptides
In order to make sure that the antibody is only binding to the right target:
Laboratory technicians will mix the antibody with phospho-peptides (short segments of the protein containing the phosphate group modification).
If the antibody signal disappears, it is confirmation that it is binding to the correct phosphorylated location.
A more robust test is to use both the phosphorylated and non-phosphorylated (dephosphorylated) versions of the protein. The antibody should react only with the phosphorylated one.
Another method sometimes utilized is to treat the sample with an enzyme, such as alkaline phosphatase, that specifically removes phosphate groups. If the antibody signal disappears after this, it also confirms specificity.
4. Genetic Confirmation
As a final step, scientists can genetically manipulate the nucleotide sequence and alter the target protein by removing the exact site where phosphorylation happens. If the antibody no longer appears to detect the modified protein, it is strong evidence supporting the antibody being specific for that phosphorylated site.
Why Buy Phospho Antibodies Through Us?
The production laboratory adheres to strict and consistent protocols prior to releasing any of these phospho-specific antibodies:
Standard methods and proper controls in all tests to ensure high quality.
These antibodies are tested and validated in different cell types and species.
High quality control criterion to ensure each batch is consistent, so you will obtain reliable results every time.
FAQ
1. What Are Phospho-Specific Antibodies?
Phospho-specific antibodies are made to detect proteins only when they have a phosphate group linked to a specific amino acid residue. This empowers scientists understand if a protein is "turned on" or active, based on its phosphorylation state.
2. How to Detect Phosphorylated Proteins in a Western Blot?
To find out if a protein is phosphorylated using Western blot:
Use a phospho-specific antibody that binds only to the phosphorylated form of the protein.
You can also use a “regular” antibody for the same amino acid sequence of the protein that the phospho-specific antibody is binding to (but in this case, this antibody will not bind if there is a phosphate group present) in order to compare how much of it is phosphorylated versus how much is non-phosphorylated (or “total” protein, if the “normal” antibody’s epitopes are non-phospho-site-specific).
3. How to Choose the Best Antibody?
Here are some simple tips to help you pick the right antibody:
Know your target
Match your sample characteristics
Confirm the intended use is appropriate
Check “host” and “type”
Check the “quality” of the presented data/images
Appraise whether the available validation meets your needs
Submit a Question
Please complete the form below and a representative will contact you as soon as possible.
Request more Information
Please complete the form below and a representative will contact you as soon as possible.
Request a Manual
Please complete the form below and a representative will contact you as soon as possible.
Request a Quote
Please complete the form below and a representative will contact you as soon as possible.